Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that one of Sweden's most accomplished horse race trainers, Madeleine Smith, has initiated a six-month pilot test of LAMPlify®. The pilot test will focus on enhancing equine health and performance through early detection of potential respiratory viruses in horses. The test will be conducted via Madeleine Smith's horse race training operation M. Smith Galopp.
Based at Bro Park, Madeleine Smith is a highly accomplished jockey and horse race trainer with over 500 wins as a jockey and 300 victories as a trainer. Her stable, M. Smith Galopp, is home to around 15 racehorses.
This pilot test represents a significant milestone for Diagonal Bio representing the Company's first collaboration within the horse race training industry. Recent efforts by Diagonal Bio have focused on pilot tests of LAMPlify® designed to support and enhance equine health in high-performance environments. This initiative aligns with the Company's broader vision to expand the use of its diagnostic tool, LAMPlify®, across diverse high-performance settings, such as horse race training.
"I look forward to testing this new technology and hope it will provide valuable insights into the health and performance of the horses. In our industry, it's crucial to act swiftly when something is amiss, and therefore LAMPlify® could become an important tool in our daily work" - Madeleine Smith, horse race trainer at M. Smith Galopp
"We are excited to enter the horse race market, which I believe has a significant need for a solution like LAMPlify®. Madeleine was very enthusiastic about starting the tests immediately, which underscores the strong demand for our technology in the equestrian sector. Several trainers I've spoken to have shared the same reaction; why hasn't something like this existed before?" - Karin Wehlin, CEO of Diagonal Bio AB (publ)
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on November 22, 2024, at 12:30 CET.
For additional information about, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.